Abediterol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Abediterol
Accession Number
DB12100
Type
Small Molecule
Groups
Investigational
Description

Abediterol has been used in trials studying the treatment of Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Chronic Obstructive Pulmonary Disease (COPD) and Asthma.

Structure
Thumb
Synonyms
Not Available
External IDs
LAS100977
Categories
UNII
QXA167CM6F
CAS number
915133-65-2
Weight
Average: 460.522
Monoisotopic: 460.21736378
Chemical Formula
C25H30F2N2O4
InChI Key
SFYAXIFVXBKRPK-QFIPXVFZSA-N
InChI
InChI=1S/C25H30F2N2O4/c26-25(27,18-8-4-3-5-9-18)17-33-15-7-2-1-6-14-28-16-22(31)19-10-12-21(30)24-20(19)11-13-23(32)29-24/h3-5,8-13,22,28,30-31H,1-2,6-7,14-17H2,(H,29,32)/t22-/m0/s1
IUPAC Name
5-[(1R)-2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl]-8-hydroxy-1,2-dihydroquinolin-2-one
SMILES
O[C@@H](CNCCCCCCOCC(F)(F)C1=CC=CC=C1)C1=C2C=CC(=O)NC2=C(O)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Abediterol.Experimental
AcebutololAcebutolol may decrease the bronchodilatory activities of Abediterol.Approved, Investigational
AlprenololAlprenolol may decrease the bronchodilatory activities of Abediterol.Approved, Withdrawn
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Abediterol.Illicit, Withdrawn
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Abediterol.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with Abediterol.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Abediterol.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Abediterol.Approved, Illicit, Investigational
AtenololAtenolol may decrease the bronchodilatory activities of Abediterol.Approved
AtomoxetineAtomoxetine may increase the tachycardic activities of Abediterol.Approved
AtosibanThe risk or severity of adverse effects can be increased when Abediterol is combined with Atosiban.Approved, Investigational
AzosemideAbediterol may increase the hypokalemic activities of Azosemide.Investigational
BendroflumethiazideAbediterol may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Abediterol.Withdrawn
BenzthiazideAbediterol may increase the hypokalemic activities of Benzthiazide.Approved
BetahistineThe therapeutic efficacy of Abediterol can be decreased when used in combination with Betahistine.Approved, Investigational
BetaxololBetaxolol may decrease the bronchodilatory activities of Abediterol.Approved, Investigational
BisoprololBisoprolol may decrease the bronchodilatory activities of Abediterol.Approved
BopindololBopindolol may decrease the bronchodilatory activities of Abediterol.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Abediterol.Experimental
BumetanideAbediterol may increase the hypokalemic activities of Bumetanide.Approved
BupranololBupranolol may decrease the bronchodilatory activities of Abediterol.Approved
ButriptylineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Abediterol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Abediterol.Withdrawn
CarteololCarteolol may decrease the bronchodilatory activities of Abediterol.Approved
CeliprololCeliprolol may decrease the bronchodilatory activities of Abediterol.Approved, Investigational
ChlorothiazideAbediterol may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorthalidoneAbediterol may increase the hypokalemic activities of Chlorthalidone.Approved
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Abediterol.Approved, Investigational, Vet Approved
CloranololCloranolol may decrease the bronchodilatory activities of Abediterol.Experimental
CyclopenthiazideAbediterol may increase the hypokalemic activities of Cyclopenthiazide.Experimental
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Abediterol.Approved, Investigational
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Abediterol.Experimental
DimetacrineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Abediterol.Approved, Withdrawn
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Abediterol.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Abediterol.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Doxofylline is combined with Abediterol.Approved, Investigational
EpitizideAbediterol may increase the hypokalemic activities of Epitizide.Experimental
EsmololEsmolol may decrease the bronchodilatory activities of Abediterol.Approved
Etacrynic acidAbediterol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Abediterol.Approved, Investigational, Vet Approved
FurosemideAbediterol may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Abediterol.Experimental
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Abediterol.Experimental
HydrochlorothiazideAbediterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideAbediterol may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Abediterol.Approved
IndapamideAbediterol may increase the hypokalemic activities of Indapamide.Approved
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Abediterol.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Abediterol.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Abediterol.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Abediterol.Approved
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Abediterol.Experimental
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Abediterol.Withdrawn
MelitracenThe risk or severity of adverse effects can be increased when Melitracen is combined with Abediterol.Experimental, Investigational
MepindololMepindolol may decrease the bronchodilatory activities of Abediterol.Experimental
MethyclothiazideAbediterol may increase the hypokalemic activities of Methyclothiazide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Abediterol.Approved, Investigational
MetolazoneAbediterol may increase the hypokalemic activities of Metolazone.Approved
MetoprololMetoprolol may decrease the bronchodilatory activities of Abediterol.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Abediterol.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Abediterol.Approved, Investigational
NadololNadolol may decrease the bronchodilatory activities of Abediterol.Approved
NebivololNebivolol may decrease the bronchodilatory activities of Abediterol.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Abediterol.Withdrawn
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Abediterol.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Abediterol.Withdrawn
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Abediterol.Investigational
OxprenololOxprenolol may decrease the bronchodilatory activities of Abediterol.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Abediterol.Approved
PenbutololPenbutolol may decrease the bronchodilatory activities of Abediterol.Approved, Investigational
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Abediterol.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Abediterol.Withdrawn
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Abediterol.Withdrawn
PindololPindolol may decrease the bronchodilatory activities of Abediterol.Approved, Investigational
PiretanideAbediterol may increase the hypokalemic activities of Piretanide.Approved
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Abediterol.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Abediterol.Withdrawn
PolythiazideAbediterol may increase the hypokalemic activities of Polythiazide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Abediterol.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Abediterol.Approved, Investigational
PropranololPropranolol may decrease the bronchodilatory activities of Abediterol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Abediterol.Approved
QuinethazoneAbediterol may increase the hypokalemic activities of Quinethazone.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Abediterol.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Abediterol.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Abediterol.Approved, Investigational, Vet Approved
SotalolSotalol may decrease the bronchodilatory activities of Abediterol.Approved
TertatololTertatolol may decrease the bronchodilatory activities of Abediterol.Experimental
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Abediterol.Approved, Investigational
TimololTimolol may decrease the bronchodilatory activities of Abediterol.Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Abediterol.Approved
TorasemideAbediterol may increase the hypokalemic activities of Torasemide.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Abediterol.Approved, Investigational
TrichlormethiazideAbediterol may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Abediterol.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Abediterol.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
11962616
PubChem Substance
347828404
ChemSpider
10136846
ChEMBL
CHEMBL3039530
Wikipedia
Abediterol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAsthma Bronchial1
1CompletedTreatmentAsthma Bronchial / Asthma, Chronic Obstructive Pulmonary Disease1
1CompletedTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD) / Chronic Obstructive Pulmonary Disease (COPD) and Asthma1
2CompletedTreatmentAsthma Bronchial1
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00458 mg/mLALOGPS
logP3.14ALOGPS
logP3.07ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)8.51ChemAxon
pKa (Strongest Basic)9.74ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area90.82 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity125.51 m3·mol-1ChemAxon
Polarizability48.29 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as hydroxyquinolones. These are compounds containing a quinoline moiety bearing a hydroxyl group and a ketone. Quinoline or benzo[b]pyridine is a bicyclic compound that consists of benzene fused to a pyridine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinolones and derivatives
Direct Parent
Hydroxyquinolones
Alternative Parents
8-hydroxyquinolines / Hydroxyquinolines / Hydroquinolones / Hydroquinolines / 1-hydroxy-2-unsubstituted benzenoids / Pyridinones / Aralkylamines / Benzene and substituted derivatives / Heteroaromatic compounds / 1,2-aminoalcohols
show 10 more
Substituents
Hydroxyquinolone / Dihydroquinolone / Hydroxyquinoline / 8-hydroxyquinoline / Dihydroquinoline / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Pyridinone / Phenol / Monocyclic benzene moiety
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:21 / Updated on July 02, 2018 19:32